Sydney-based drug development company Nyrada Inc (ASX:NYR) has completed an in vivo micronucleus study on rats which has supported expectations of safety for its NYR-BI03 drug candidate – particularly in terms of genetic damage – ahead of Phase 1 human trials later this year. The study – completed as part of Nyrada’s brain injury program Good Laboratory Practices (GLP) – found there was no increase in markers of genotoxicity in treated animals compared with control treated animals. NYR-BI03 is being developed to treat both stroke and traumatic brain injury (TBI), and these results follow on fr…